6,404 Shares in Johnson & Johnson (NYSE:JNJ) Bought by Leigh Baldwin & CO. LLC

Leigh Baldwin & CO. LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, Holdings Channel.com reports. The fund purchased 6,404 shares of the company’s stock, valued at approximately $926,000.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Tallon Kerry Patrick acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $290,000. Capital & Planning LLC lifted its holdings in shares of Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after purchasing an additional 183 shares during the period. Tide Cove Capital Partners LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $2,448,000. MCF Advisors LLC lifted its holdings in shares of Johnson & Johnson by 6.0% during the fourth quarter. MCF Advisors LLC now owns 15,000 shares of the company’s stock worth $2,169,000 after purchasing an additional 852 shares during the period. Finally, Red Spruce Capital LLC lifted its holdings in shares of Johnson & Johnson by 5.3% during the fourth quarter. Red Spruce Capital LLC now owns 12,161 shares of the company’s stock worth $1,759,000 after purchasing an additional 617 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JNJ. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Barclays reduced their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $153.12 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $368.41 billion, a P/E ratio of 23.02, a PEG ratio of 2.56 and a beta of 0.42. The company has a 50-day moving average of $155.24 and a two-hundred day moving average of $153.69. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.40%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.